Ursodeoxycholate improves hepatobiliary dysfunction induced by valproate-carbamazepine treatment in the rat

Life Sciences

Volumn 59, Issue 13, 1996, Pages 1069-1079

  Mesdjian, E ^a   Zamora, A J ^b   Montet, A M ^c   Bonneton, J ^a   Guitaoui, M ^c   Genton, P ^a   Montet, J C ^c  

^a Ctr S Paul et Lab de Biol M   (France)

^b Institut Jean Roche   (France)

^c INSERM   (France)

Author keywords

Carbamazepine; Hepatotoxicity; Ursodeoxycholate; Valproate

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; DRUG METABOLITE; LIVER PROTECTIVE AGENT; PHOSPHOLIPID; URSODEOXYCHOLIC ACID; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEPATOBILIARY SYSTEM; INTRAGASTRIC DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER TOXICITY; MALE; NONHUMAN; RAT;

ANIMALIA;

EID: 0030598967     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/0024-3205(96)00422-5     Document Type: Article

References (31)

1. 1. A.K. GUPTA, and P.M. JEAVONS, J Neurol Neurosur Ps, 48 1010-1014 (1985).
2. 2. E. KORN-MERKER, W. KORING, A. SALKE, and H.E. BOENIGK, Epilepsia, 32 85 (1991).
3. 3. M. LEVY, M.W. GOODMAN, B. VAN DYNE, and H.W. SUMMER, Ann Intern Med, 95 64-65 (1981).
4. 4. S. HOROWITZ, R. PATWARDHAN, and E. MARCUS, Epilepsia, 29 149-154 (1988).
5. 5. P.M. JEAVONS, Dev Med Child Neurol, 22 547-548 (1980).
6. 6. F.E. DREIFUSS, N. SANTILLI, D.H. LANGER, K.P. SWEENEY, K.A. MOLINE, and K.B. MENANDER, Neurology, 37 379-385 (1987)
7. 7. S.M. BJORGE, and T.A. BAILLIE, Drug Metab Dispos, 19 823-829 (1991).
8. 8. R.E. POUPON, B. BALKAU, E. ESCHWÈGE, R. POUPON and the UDCA-PBC study group, N Engl J Med, 324 1548-1554 (1991).
9. 9. C. GALABERT, J.C. MONTET, D. LENGRAND, A. LECUIRE, C. SOTTA, C. FIGARELLA and J.P. CHAZALETTE, J Pediatr, 121 138-141 (1992).
10. 10. X.M. ZHAO, and J.C. MONTET, J Nutr Biochem, 1 420-425 (1990).
11. 11. P.E. QUENEAU, P. BERTAULT-PÉRÈS, E. MESDJIAN, A. DURAND, and J.C. MONTET, Transplantation, 56 530-534 (1993).
12. 12. P.E. QUENEAU, P. BERTAULT-PÉRÈS, M. GUITAOUI, E. MESDJIAN, A. DURAND, and J.C. MONTET, Dig Dis Sci, 39 1581-1585 (1994).
13. 13. S. GÜLDÜTUNA, G. ZIMMER, M. IMHOF, S. BHATTI, T. YOU, and U. LEUSCHNER, Gastroenterology, 104 1736-1744 (1993).
14. 14. P.E. QUENEAU, and J.C. MONTET, J Hepatol 21 260-268 (1994).
15. 15. R. BOTLA, J.R. SPIVEY, H. AGUILAR, S.F. BRONK, and G.J. GORES, J Pharmacol Exp Ther, 272 930-938 (1995).
16. 16. B.C. ROSSER, and G.J. GORES, Gastroenterology, 108 252-275 (1995).
17. 17. A.M. JEZEQUEL, P. BONAZZI, G. NOVELLI, C. VENTURINI, and F. ORLANDI, Hepatology, 4 1159-1166 (1984).
18. 18. M.E. BELLRINGER, K. RAHMAN, and R. COLEMAN, Biochem J, 249 513-519 (1988).
19. 19. G.F. CARL, and M.L. SMITH, Epilepsia, 30 217-224 (1989).
20. 20. S.B. TURLEY and J.M. DIETSCHY, J. Lipid Res. 19 924-928 (1978).
21. 21. J. AMIC, D. LAIRON, and J. HAUTON, Clin. Chim. Acta 40, 107-114 (1972).
22. 22. A.A. ELYAS, N. RATNARAJ, V.D. GOLDBERG, and P.T. LASCELLES, J Chromatogr, 231 93-101 (1982).
23. 23. P. LOISEAU, A. BRACHET, and P. HENRI, Epilepsia, 16 609-615 (1975).
24. 24. M.J. KARNOVSKY, J Cell Biol, 21 137 A (1965).
25. 25. H.J.G. GUNDERSEN, and E.B. JENSEN, J Microsc. 147, 229-263 (1987)
26. 26. D. HAIDUKEWYCH, and G. JOHN, Ther Drug Monit, 8 407-410 (1986).
27. 27. R.H. LEVY, T.A. MORELAND, P.L. MORSELLI, M. GUYOT, A. BRACHET-LIERMAIN, and P. LOISEAU, Epilepsia, 25 338-345 (1984).
28. 28. T.A. BOWDLE, R.H. LEVY, and R.E. CUTLER, Clin Pharmacol Ther, 26 629-634 (1979).
29. 29. E. MESDJIAN, C. DRAVET, and J ROGER, Metabolism of antiepileptic drugs. Levy RH, Pitlick WH, Eichelbaum M, Meijer J (Eds), 115-123 Raven Press, New York (1984).
30. 30. J.B. WATKINS, and C.D. KLAASEN, J Pharmacol Exp Ther, 220 305-310 (1982).
31. 31. H.J. VERKADE, M.J. WOLBERS, R. HAVINGA, D.R. UGES, R.J. VONK, and F. KUIPERS, Gastroenterology, 99 1485-1492 (1990).